Biomarkers in colorectal cancer.
Systemic therapies available for treatment of colorectal cancer have increased in recent years, leading to improved clinical outcomes. However, a significant proportion of patients fail to derive meaningful benefits, whereas others suffer from unacceptable toxicities. Therefore, not only does the search for novel and effective anticancer agents continue, there is also a pressing need to optimise the use of all treatments in the therapeutic armamentarium. In addition to knowledge gleaned from well-designed and relevant clinical trials, increasing effort is being invested into biomarkers. The identification and implementation of validated biomarkers has the potential to further our understanding of the biology of colorectal cancer and also to greatly improve the efficiency with which cancer treatments are administered.
Markman
B
B
Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Rodríguez-Freixinos
V
V
Tabernero
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics*; D016503:Drug Delivery Systems / Q000379:methods; D055808:Drug Discovery / Q000379:methods; D006801:Humans
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
Anticancer Res. 2007 Jan-Feb;27(1B):627-33
17348452
J Clin Invest. 1996 Aug 1;98(3):610-5
8698850
J Clin Oncol. 2009 Apr 10;27(11):1814-21
19273709
Ann Oncol. 2008 May;19(5):915-9
18245778
J Clin Oncol. 2007 Aug 1;25(22):3230-7
17664471
J Clin Oncol. 2004 Apr 15;22(8):1382-8
15007088
Oncology. 2006;70(5):366-77
17179731
BMC Cancer. 2009 Sep 24;9:339
19775480
Ann Oncol. 2009 Jul;20(7):1223-9
19282466
Cancer Res. 1998 Nov 15;58(22):5248-57
9823339
J Clin Oncol. 2006 Nov 20;24(33):5313-27
17060676
J Clin Oncol. 2008 Dec 10;26(35):5705-12
19001320
Ann Oncol. 2010 Apr;21(4):772-780
19833818
J Clin Oncol. 2004 Feb 1;22(3):529-36
14752076
Cancer Res. 2008 Mar 15;68(6):1953-61
18339877
J Clin Oncol. 2005 Jan 20;23(3):609-18
15659508
J Clin Oncol. 2009 Mar 1;27(7):1122-9
19164213
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
11240971
N Engl J Med. 2008 Oct 23;359(17):1757-65
18946061
Pharmacogenomics J. 2002;2(1):43-7
11990381
Br J Cancer. 2010 Jan 5;102(1):162-4
19953097
Carcinogenesis. 2004 Apr;25(4):527-33
14688025
J Clin Oncol. 2004 Apr 1;22(7):1201-8
14993230
Clin Cancer Res. 2009 May 1;15(9):3184-8
19366826
Cancer Res. 2009 Mar 1;69(5):1851-7
19223544
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
J Clin Oncol. 2008 Apr 1;26(10):1626-34
18316791
J Clin Oncol. 2001 Dec 1;19(23):4298-304
11731512
N Engl J Med. 2007 Nov 15;357(20):2040-8
18003960
Br J Cancer. 2008 Oct 7;99(7):1050-5
18797464
J Clin Oncol. 2008 Jun 1;26(16):2690-8
18509181
J Clin Oncol. 2009 Dec 10;27(35):5924-30
19884556
J Clin Oncol. 2007 Mar 1;25(7):767-72
17228023
Br J Cancer. 2005 Feb 14;92(3):434-44
15668707
N Engl J Med. 2004 Dec 30;351(27):2883
15625347
J Surg Res. 2005 Apr;124(2):169-74
15820244
Br J Cancer. 2001 Sep 1;85(5):692-6
11531254
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2652-7
18268322
J Clin Oncol. 2009 Oct 20;27(30):5068-74
19738126
Clin Cancer Res. 2000 Apr;6(4):1322-7
10778957
J Clin Oncol. 2009 Apr 20;27(12):2091-6
19188670
Int J Cancer. 1997 Jan 27;70(3):335-40
9033637
N Engl J Med. 1996 Dec 5;335(23):1727-32
8929264
J Natl Cancer Inst. 1998 May 6;90(9):675-84
9586664
J Clin Oncol. 2007 Aug 1;25(22):3238-45
17664472
N Engl J Med. 2009 Apr 2;360(14):1408-17
19339720
N Engl J Med. 2003 Jul 17;349(3):247-57
12867608
J Clin Oncol. 2008 Jul 1;26(19):3213-21
18591556
Ann Oncol. 2009 May;20(5):879-84
19179548
N Engl J Med. 1994 Jul 28;331(4):213-21
8015568
Lancet Oncol. 2005 May;6(5):279-86
15863375
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 2005 Mar 20;23(9):1803-10
15677699
J Clin Oncol. 2009 Feb 10;27(5):663-71
19114683
J Clin Oncol. 2003 Jan 15;21(2):241-50
12525515
Clin Cancer Res. 2009 Dec 1;15(23):7322-9
19934290